Breast cancer (Tokyo, Japan) · 2025
Prospective randomized-controlled trial: efficacy of 37 °C-preheated thermoplastic elastomer (TPE) bolus in postoperative radiotherapy for breast cancer patients.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Lihua, Li Bo, Wang Rong, Li Jie, Cai Rong, Zhang Fengbin, Yang Fating, Liu Zixuan, Yang Lin, Ma Juan, Yao Xiaowei, Hu Qiuxia, Xu Linlin, Zang Jian, Bai Fei, Zhao Lina
Аннотация
OBJECTIVE: This randomized-controlled trial aimed to investigate whether preheating thermoplastic elastomer (TPE) bolus to 37 °C reduces setup errors and improves patient comfort during post-mastectomy radiotherapy (PMRT).
METHODS: From July 2023 to June 2024, breast cancer patients requiring PMRT were randomized (1:1) to receive either preheated (37 °C, 30 min) or room-temperature TPE bolus. Bolus was applied during the first half of treatment (15/25 or 8/15 fractions). Weekly cone-beam computed tomography (CBCT) assessed setup errors (lateral [Lat], longitudinal [Lng], vertical [Vrt], and rotational [Rtn]). Secondary endpoints included thorax anteroposterior diameter changes (ΔZ), skin toxicity (CTCAE v3.0), and comfort (modified Likert scale).
RESULTS: Among 154 analyzed patients, preheating significantly reduced Vrt (0.24 ± 2.43 mm vs. - 0.64 ± 2.46 mm, p < 0.01) and Lat errors (- 0.12 ± 2.49 mm vs. 0.63 ± 2.49 mm, p < 0.01). The preheating group reported higher temperature comfort scores (4.32 ± 0.55 vs. 3.59 ± 0.72, p < 0.01). No significant differences were observed in Grade 2 (46.6% vs. 44.3%, p = 0.661) or Grade 3 (2.7% vs. 2.9%, p = 1.000) radiation dermatitis.
CONCLUSION: Preheated TPE bolus improves setup accuracy in the Vrt and Lat directions, enhances patient comfort, and maintains skin safety, supporting its clinical utility in PMRT.
METHODS: From July 2023 to June 2024, breast cancer patients requiring PMRT were randomized (1:1) to receive either preheated (37 °C, 30 min) or room-temperature TPE bolus. Bolus was applied during the first half of treatment (15/25 or 8/15 fractions). Weekly cone-beam computed tomography (CBCT) assessed setup errors (lateral [Lat], longitudinal [Lng], vertical [Vrt], and rotational [Rtn]). Secondary endpoints included thorax anteroposterior diameter changes (ΔZ), skin toxicity (CTCAE v3.0), and comfort (modified Likert scale).
RESULTS: Among 154 analyzed patients, preheating significantly reduced Vrt (0.24 ± 2.43 mm vs. - 0.64 ± 2.46 mm, p < 0.01) and Lat errors (- 0.12 ± 2.49 mm vs. 0.63 ± 2.49 mm, p < 0.01). The preheating group reported higher temperature comfort scores (4.32 ± 0.55 vs. 3.59 ± 0.72, p < 0.01). No significant differences were observed in Grade 2 (46.6% vs. 44.3%, p = 0.661) or Grade 3 (2.7% vs. 2.9%, p = 1.000) radiation dermatitis.
CONCLUSION: Preheated TPE bolus improves setup accuracy in the Vrt and Lat directions, enhances patient comfort, and maintains skin safety, supporting its clinical utility in PMRT.